Hyloris Pharmaceuticals (XBRU:HYL) EPS (Diluted) : €-0.56 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals EPS (Diluted)?

Hyloris Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.56.

Hyloris Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2023 was €-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.56.

Hyloris Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was €-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.56.

During the past 3 years, the average EPS without NRIGrowth Rate was -19.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Hyloris Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -19.10% per year. The lowest was -28.20% per year. And the median was -21.30% per year.

Hyloris Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Hyloris Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals EPS (Diluted) Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-0.23

-0.33

-0.45

-0.40

-0.56

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial							-0.13	-0.18	-0.21	-0.24	-0.33

Competitive Comparison of Hyloris Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Hyloris Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's PE Ratio falls into.

Hyloris Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Hyloris Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-15.762	-	0)	/	28.0004
	=	-0.56

Hyloris Pharmaceuticals's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-9.128	-	0)	/	28.0004
	=	-0.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.56

Hyloris Pharmaceuticals (XBRU:HYL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hyloris Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.